Renin-angiotensin system blockade and reduction of cardiovascular risk: Future perspectives

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 12, 2011, Pages 1585-1591

  De La Sierra, Alejandro ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

cardiorenal continuum; cardiovascular disease; prevention; rennin angiotensin system; residual risk; silent organ damage

Indexed keywords

ALDOSTERONE RECEPTOR; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; RENIN INHIBITOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; COUGHING; DRUG MECHANISM; DRUG POTENTIATION; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MORBIDITY; MORTALITY; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SURVIVAL RATE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; HEALTH PROMOTION; HUMANS; HYPERTENSION; LIFE STYLE; PROTEASE INHIBITORS; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 82755174016     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.164     Document Type: Review

References (60)

1. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. 23(Suppl. 1), S9-S17 (2005).
2. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28, 2375-2414 (2007).
3. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 53, 480-485 (2009).
4. Nicotra F, Wettermark B, Sturkenboom MC et al. Management of antihypertensive drugs in three European countries. J. Hypertens. 27, 1917-1922 (2009).
5. De la Sierra A, Ruilope LM, Coca A, Luque-Otero M. [Relationship between cardiovascular risk profile and anti-hypertensive drug use]. Med. Clin. (Barc.) 115, 41-45 (2000). (Pubitemid 30497844)
6. Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: still HOPE for ACE inhibitors? Exp. Opin. Pharmacother. 12, 839-843 (2011).
7. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355, 1575-1581 (2000). (Pubitemid 30240501)
8. Garg R, Yusuf S. Overview of randomized trial of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273, 1450-1456 (1995).
9. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358, 1033-1041 (2001).
10. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
12. Sierra C, de la Sierra A. Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers. Curr. Opin. Nephrol. Hypertens. 14, 435-441 (2005). (Pubitemid 41152705)
13. Granger CB, McMurray JJ, Yusf S et al. Effects of candesartan on in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772-776 (2003). (Pubitemid 37093917)
14. The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372, 1174-1183 (2008).
15. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003). (Pubitemid 37409706)
16. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
17. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002). (Pubitemid 34286536)
18. Schrader J, Lders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218-1226 (2005).
19. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363, 2022-2031 (2004). (Pubitemid 38781102)
20. De la Sierra A, Salazar J. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient? Adv Ther. 28, 716-727 (2011
21. De la Sierra A, Ruilope LM. [Can we achieve a greater reduction of cardiovascular mortality and morbidity in patients already treated with renin- angiotensin system blockers?]. Med. Clin. (Barc.) 135, 212-214 (2010).
22. Beaglehole R, Bonita R, Horton R et al. Priority actions for the non-communicable disease crisis. Lancet 377, 1438-1447 (2011).
23. Annand SS, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 377, 529-532 (2011).
24. Sacks FM, Svetkey LP, Vollmer WM et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N. Engl. J. Med. 344, 3-10 (2001). (Pubitemid 32064838)
25. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JNC 7 - complete version. Hypertension 42, 1206-1252 (2003). (Pubitemid 37553153)
26. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J. Hypertens. 22, 11-19 (2004). (Pubitemid 38293521)
27. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289, 2363-2369 (2003). (Pubitemid 37430168)
28. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373, 929-940 (2009).
29. Chobanian AV. Shattuck Lecture. The hypertension paradox - more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361, 878-887 (2009).
30. De la Sierra A. Blood pressure control in the hypertensive population. What else the doctor can do? J. Hypertens. 28, 1129-1130 (2010).
31. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002).
32. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005). (Pubitemid 40471450)
33. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004). (Pubitemid 39140624)
34. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003). (Pubitemid 36398384)
35. Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension. J. Hypertens. 25, 1105-1187 (2007).
36. The ACCORD Study Group. Effects of intensive blood-pressure control in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
37. The ACCORD Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
38. Sleight P, Redon J, Verdecchia P et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 27, 1360-1369 (2009).
39. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009).
40. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003). (Pubitemid 36159355)
41. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008). (Pubitemid 351214285)
42. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005). (Pubitemid 41265663)
43. Sever P, Dahlöf B, Poulter N et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur. Heart J. 27, 2982-2988 (2006). (Pubitemid 44950442)
44. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in Type 2 diabetes mellitus. J. Hypertens. 25, 1921-1926 (2007). (Pubitemid 47356634)
45. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with Type 2 diabetes and microalbuminuria. Kidney Int. 68, 1190-1198 (2005). (Pubitemid 43246436)
46. Burgess E, Muirhead N, Rene de Cotret P et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. 20, 893-900 (2009).
47. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008). (Pubitemid 351688350)
48. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; for the AVOID Study Investigators. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008). (Pubitemid 351793017)
49. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361, 117-124 (2003). (Pubitemid 36092015)
50. Retraction: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 374, 1226 (2009
51. Cohn J, Tognoni G. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001). (Pubitemid 33126822)
52. McMurray JJ, Östergren J, Swedberg K et al. Effects of candesartan on patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771 (2003).
53. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24, 1663-1669 (2009).
54. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2641-2650 (2009).
55. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999). (Pubitemid 29407370)
56. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003). (Pubitemid 36384098)
57. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11-21 (2011).
58. Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. 351, 543-551 (2004). (Pubitemid 39025171)
59. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
60. Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375, 1173-1181 (2010